2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Aminoglycosides intervention, Lack of protective isolation intervention, No systematic aminoglycosides intervention - standard arm - Sepsis, Septic Shock | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 340 | 2022-09-01 | 2022-07-05 |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day - Graft Versus Host Disease, Hematologic Malignancy | Phase 3 | Unknown | National Research Center for Hematology, Russia | 100 | 2022-01-01 | 2022-01-11 |
Hematologic Neoplasms (2) · Graft vs Host Disease (1) · Neoplasms (1) · Sepsis (1) · Shock, Septic (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms by Site (2) · Immune System Diseases (1) · Infections (1) · Inflammation (1) · Neoplasms (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Shock (1) · Systemic Inflammatory Response Syndrome (1)
Cyclophosphamide (1) · trihexyltetradecylphosphonium chloride (1)
Assistance Publique - Hôpitaux de Paris (1) · National Research Center for Hematology, Russia (1)